

Shahla Bari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6443869/publications.pdf>

Version: 2024-02-01

7
papers

51
citations

1937685

4
h-index

2053705

5
g-index

9
all docs

9
docs citations

9
times ranked

60
citing authors

#	ARTICLE	IF	CITATIONS
1	Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110516.	2.0	8
2	Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-5.	1.3	17
3	Anti- α and anti- β immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC 201: case report and review of the literature. <i>Transfusion</i> , 2019, 59, 1907-1910.	1.6	20
4	2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. <i>Open Forum Infectious Diseases</i> , 2018, 5, S663-S663.	0.9	0
5	Comparison of Pre- and Post-translational Expressions of COXIV-1 and MT-ATPase 6 Genes in Colorectal Adenoma-Carcinoma Tissues [NIH-NIGMS]. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2018, 09, .	0.3	4
6	Prognostic significance of microsatellite instability (MSI) and mismatch repair status (MMR) in African American (AA) patients with colorectal cancer (CRC) and its impact on therapy with 5Fluorouracil.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15634-e15634.	1.6	0
7	Efficacy and safety profile of PD-1 and pdl-1 inhibitors in African American patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15080-e15080.	1.6	0